ERBB2 and breast cancer: The sensitivity of using breast pCR as a diagnostic test to identify ypN0 in different biological subtypes of cN0 breast cancer patients receiving NAC is very high, ranging from 96.3% for HR-positive/HER2-negative to 99.1% for HR-negative/HER2-positive.